전립선 건강 시장 2026년까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤드마켓츠)출판년월 : 2021년12월

・질병 적응증(전립선암, PARP 억제제, 세포독성 약물, 양성 전립선 비대증(BPH), 탐스로신, 5 알파 환원효소, 전립선염, OTC, 처방(Rx), 지역(북미, 유럽, APAC) – 2026 년까지의 세계 예측

Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) – Global Forecasts to 2026

페이지수 95
도표수 135
구성 영문조사보고서
가격

리포트목차보기    견적・문의・의뢰로 이동    구입안내

SAMPLE Request

 

 

The global prostate health market is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period. The prostate gland (the prostate) is an organ of the male reproductive system. The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer. Benign prostatic hyperplasia (BPH) is defined as a medical condition affecting men. It involves the non-cancerous enlargement of the prostate gland. While BPH rarely shows symptoms before the age of 40, the risk of contracting BPH increases with age. The condition affects nearly 50% of men between the ages of 51 and 60 and up to 90% of men older than 80. Treatment measures such as medications and surgery have been used for patients with BPH.
전 세계 전립선 건강 시장은 예측 기간 동안 CAGR 9.0%로 2021년 318억 달러에서 2026년 489억 달러에 이를 것으로 예상됩니다. 전립선(전립선)은 남성 생식 기관의 기관입니다. 전립선 질환의 가장 흔한 3가지 형태는 염증(전립선염), 전립선의 비암성 비대(양성 전립선 비대증 또는 BPH) 및 전립선암입니다. 양성 전립선 비대증(BPH)은 남성에게 영향을 미치는 의학적 상태로 정의됩니다. 그것은 전립선의 비암성 확대를 포함합니다. BPH는 40세 이전에 증상을 거의 나타내지 않지만 BPH에 걸릴 위험은 나이가 들수록 증가합니다. 이 상태는 51~60세 남성의 거의 50%, 80세 이상 남성의 최대 90%에 영향을 미칩니다. 약물 및 수술과 같은 치료 방법은 BPH 환자에게 사용되었습니다.
Prostate Cancerto hold thelargestsegmentof the market
Based on disease indication, the prostate health market is segmented into prostate cancer, benign prostate hyperplasia, and prostatitis. In 2020, prostate cancer accounted for the largest share in the prostate health market. Typically, hormone therapy is considered an effective option as the first line of treatment for prostate cancer. Cancer vaccines, radiopharmaceutical agents, secondary hormone therapies, or chemotherapies follow hormonal therapy as treatment options. Cancerous cells are found to be developing a resistance to these therapies after some months, as a result of which immunotherapies are expected to be adopted widely for the treatment of prostate cancer in the near future.

The US to dominate theprostate health market in North America
The prostate health market is segmented into five six regions—North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has been among the frontrunners in developing prostate health therapiesin the healthcare industry. The market growth in the US (a major contributor to the North American prostate health market) can be mainly attributed to the growing target population, the high incidence of BPH, prostate cancer, and prostatitis, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong healthcare infrastructure, research funding, and product launches have accelerated the growth of this market.

Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35% • By Designation:Director-level – 30%, C-level – 20%, and Others – 50% • By Region: North America – 33%, Europe – 24%, APAC –27%, Rest of the World –16%
Some of the prominent players operating in the prostate healthmarket are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan) and other players.

Research Coverage
This report studies the prostate health market based on type, mode of purchase, and application, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to two main geographies – source and destination.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.


목차

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 20
1.5 STAKEHOLDERS 20
1.6 LIMITATIONS OF THE CURRENT EDITION OF THE REPORT 20
2 RESEARCH METHODOLOGY 21
2.1 RESEARCH DATA 21
FIGURE 1 RESEARCH DESIGN 21
2.1.1 SECONDARY DATA 22
2.1.1.1 Key data from secondary sources 22
2.1.2 PRIMARY DATA 23
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 23
2.1.2.1 Key data from primary sources 23
2.2 MARKET SIZE ESTIMATION 24
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 24
2.2.1 BOTTOM-UP APPROACH 25
2.2.2 GROWTH FORECAST 25
2.2.3 TOP-DOWN APPROACH 25
FIGURE 4 PROSTATE HEALTH MARKET: TOP-DOWN APPROACH 25
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 26
FIGURE 5 DATA TRIANGULATION METHODOLOGY 26
2.4 ASSUMPTIONS FOR THE STUDY 27
3 MARKET DYNAMICS 28
3.1 MARKET DYNAMICS 28
FIGURE 6 PROSTATE HEALTH MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 28
3.1.1 DRIVERS 29
3.1.1.1 Increasing prevalence of benign prostatic hyperplasia 29
FIGURE 7 SHARE OF THE MALE POPULATION AGED 65 AND ABOVE, GLOBAL
(2015-2019) 29
3.1.1.2 Increasing obesity 29
3.1.1.3 Investments, funds, and grants for research in BPH treatment 30
3.1.1.4 Rising prevalence of prostate cancer 30
3.1.1.5 Increasing demand for hormone therapy drugs 30
3.1.1.6 Emerging therapies for prostate cancer 31
TABLE 1 SELECT THERAPIES IN THE PHASE III PIPELINE FOR PROSTATE CANCER 31
3.1.2 RESTRAINTS 31
3.1.2.1 Side-effects associated with BPH medications 31
TABLE 2 SIDE-EFFECTS OF BPH DRUGS 32
3.1.3 OPPORTUNITIES 32
3.1.3.1 Emerging markets 32
3.1.3.2 Promising product pipeline 33
TABLE 3 PIPELINE DRUGS 33
3.1.4 CHALLENGES 33
3.1.4.1 Low awareness regarding prostate health among men 33
3.1.4.2 Product recalls in the prostate health market 33
TABLE 4 PRODUCT RECALLS IN THE PROSTATE HEALTH MARKET 34
4 PROSTATE HEALTH MARKET, BY DISEASE TYPE 35
4.1 INTRODUCTION 36
TABLE 5 PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION) 36
4.2 PROSTATE CANCER 36
TABLE 6 PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 36
TABLE 7 PROSTATE CANCER MARKET, BY REGION, 2018–2026 (USD MILLION) 37
4.2.1 AR-DIRECTED THERAPIES 37
4.2.1.1 AR-directed therapies are expected to remain the dominant drug class for the treatment of prostate cancer 37
TABLE 8 AR-DIRECTED THERAPIES MARKET, BY REGION, 2018–2026 (USD MILLION) 37
4.2.2 HORMONE ADT 38
4.2.2.1 ADT is the most common form of hormonal treatment 38
TABLE 9 HORMONAL ADT MARKET, BY REGION, 2018–2026 (USD MILLION) 38
4.2.3 CYTOTOXIC AGENTS 38
4.2.3.1 Newer cytotoxic agents are being studied in prostate cancer with the goal of achieving FDA approvals 38
TABLE 10 CYTOTOXIC AGENTS MARKET, BY REGION, 2018–2026 (USD MILLION) 38
4.2.4 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS 39
4.2.4.1 PARP inhibitors are expected to be the leading drug class for the treatment of prostate cancer 39
TABLE 11 PARP INHIBITORS MARKET, BY REGION, 2018–2026 (USD MILLION) 39
4.2.5 OTHER THERAPIES 39
TABLE 12 OTHER THERAPIES MARKET, BY REGION, 2018–2026 (USD MILLION) 39
4.3 BENIGN PROSTATIC HYPERPLASIA 40
TABLE 13 BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 40
TABLE 14 BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION) 40
4.3.1 ALPHA BLOCKERS 41
TABLE 15 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,
2018–2026 (USD MILLION) 41
TABLE 16 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION,
2018–2026 (USD MILLION) 41
4.3.1.1 Tamsulosin 42
4.3.1.1.1 Tamsulosin has been prescribed for BPH since 2000 42
TABLE 17 TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION) 42
4.3.1.2 Silodosin 42
4.3.1.2.1 Benefits of silodosin and the launch of generics to support market growth 42
TABLE 18 SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION) 43
4.3.1.3 Alfuzosin 43
4.3.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent 43
TABLE 19 ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION) 43
4.3.1.4 Doxazosin 44
4.3.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since 44
TABLE 20 DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION) 44
4.3.1.5 Other alpha blockers 44
TABLE 21 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION) 45
4.3.2 5-ALPHA REDUCTASE INHIBITORS 45
TABLE 22 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 45
TABLE 23 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION,
2018–2026 (USD MILLION) 46
4.3.2.1 Dutasteride 46
4.3.2.1.1 Availability of generics post-patent expiry to support market growth 46
TABLE 24 DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION) 46
4.3.2.2 Finasteride 47
4.3.2.2.1 Finasteride is less effective than alpha blockers in improving LUTS 47
TABLE 25 FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION) 47
4.3.3 OTHER DRUG CLASSES 47
TABLE 26 OTHER BPH DRUG CLASSES MARKET, BY REGION,
2018–2026 (USD MILLION) 48
4.4 PROSTATITIS 48
TABLE 27 PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 48
TABLE 28 PROSTATITIS MARKET, BY REGION, 2018–2026 (USD MILLION) 48
4.4.1 PRESCRIPTION PRODUCTS 49
4.4.1.1 Prescription drugs account for the larger share of the products used for the treatment of prostatitis 49
TABLE 29 PRESCRIPTION PRODUCTS MARKET, BY REGION, 2018–2026 (USD MILLION) 49
4.4.2 OVER-THE-COUNTER PRODUCTS 49
4.4.2.1 Sales of OTC products have risen over the past few years 49
TABLE 30 OVER-THE-COUNTER PRODUCTS MARKET, BY REGION,
2018–2026 (USD MILLION) 50
5 PROSTATE HEALTH MARKET, BY REGION 51
5.1 INTRODUCTION 52
TABLE 31 PROSTATE HEALTH MARKET, BY REGION, 2018–2026 (USD MILLION) 52
5.2 NORTH AMERICA 52
TABLE 32 NORTH AMERICA: PROSTATE HEALTH MARKET, BY COUNTRY,
2018–2026 (USD MILLION) 53
TABLE 33 NORTH AMERICA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 53
TABLE 34 NORTH AMERICA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 53
TABLE 35 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 54
TABLE 36 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 54
TABLE 37 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR 5-ARIS,
BY TYPE, 2018–2026 (USD MILLION) 54
TABLE 38 NORTH AMERICA: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 55
5.2.1 US 55
5.2.1.1 The US holds the largest share of the North American market 55
TABLE 39 US: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 55
TABLE 40 US: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 56
TABLE 41 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 56
TABLE 42 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,
2018–2026 (USD MILLION) 56
TABLE 43 US: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 57
TABLE 44 US: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 57
5.2.2 CANADA 57
5.2.2.1 Rising geriatric population and product approvals to support market growth 57
TABLE 45 CANADA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 58
TABLE 46 CANADA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 58
TABLE 47 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 58
TABLE 48 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION) 59
TABLE 49 CANADA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 59
TABLE 50 CANADA: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 59
5.3 EUROPE 60
TABLE 51 EUROPE: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 60
TABLE 52 EUROPE: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 60
TABLE 53 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 60
TABLE 54 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 61
TABLE 55 EUROPE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 61
TABLE 56 EUROPE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 61
TABLE 57 EUROPE: PROSTATE HEALTH MARKET, BY COUNTRY,
2018–2026 (USD MILLION) 62
5.3.1 GERMANY 62
5.3.1.1 Increasing healthcare expenditure to support German market growth 62
TABLE 58 GERMANY: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 62
TABLE 59 GERMANY: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 63
TABLE 60 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 63
TABLE 61 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION) 63
TABLE 62 GERMANY: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 64
TABLE 63 GERMANY: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 64
5.3.2 UK 64
5.3.2.1 Availability of innovative treatment options to drive the market in
the UK 64
TABLE 64 UK: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 65
TABLE 65 UK: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 65
TABLE 66 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION) 65
TABLE 67 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,
2018–2026 (USD MILLION) 66
TABLE 68 UK: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 66
TABLE 69 UK: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 66
5.3.3 FRANCE 67
5.3.3.1 Rising geriatric population to accelerate the growth of the market 67
TABLE 70 FRANCE: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 67

TABLE 71 FRANCE: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 67
TABLE 72 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 68
TABLE 73 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION) 68
TABLE 74 FRANCE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 68
TABLE 75 FRANCE: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 69
5.3.4 REST OF EUROPE 69
TABLE 76 ROE: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 69
TABLE 77 ROE: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 70
TABLE 78 ROE: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 70
TABLE 79 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION) 70
TABLE 80 ROE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 71
TABLE 81 ROE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 71
5.4 ASIA PACIFIC 71
TABLE 82 ASIA PACIFIC: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 71
TABLE 83 ASIA PACIFIC: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 72
TABLE 84 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 72
TABLE 85 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION) 72
TABLE 86 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 73
TABLE 87 ASIA PACIFIC: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 73
TABLE 88 ASIA PACIFIC: PROSTATE HEALTH MARKET, BY COUNTRY,
2018–2026 (USD MILLION) 73
5.4.1 JAPAN 74
5.4.1.1 Japan holds the largest share of the APAC market 74
TABLE 89 JAPAN: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 74
TABLE 90 JAPAN: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 75
TABLE 91 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 75
TABLE 92 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION) 75

TABLE 93 JAPAN: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 76
TABLE 94 JAPAN: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 76
5.4.2 CHINA 76
5.4.2.1 Increasing obese population to support market growth 76
TABLE 95 CHINA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 77
TABLE 96 CHINA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 77
TABLE 97 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 77
TABLE 98 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 78
TABLE 99 CHINA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 78
TABLE 100 CHINA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 78
5.4.3 INDIA 79
5.4.3.1 Rising prevalence of obesity to accelerate market growth in India 79
TABLE 101 INDIA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 79
TABLE 102 INDIA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 79
TABLE 103 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 80
TABLE 104 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION) 80
TABLE 105 INDIA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 80
TABLE 106 INDIA: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 80
5.4.4 REST OF ASIA PACIFIC 81
TABLE 107 ROAPAC: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 81
TABLE 108 ROAPAC: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 81
TABLE 109 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 82
TABLE 110 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 82
TABLE 111 ROAPAC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 82
TABLE 112 ROAPAC: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 83

5.5 LATIN AMERICA 83
5.5.1 LATAM MARKETS DRIVEN BY GROWING PATIENT BASE 83
TABLE 113 LATAM: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 83
TABLE 114 LATAM: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 83
TABLE 115 LATAM: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 84
TABLE 116 LATAM: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 84
TABLE 117 LATAM: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 84
TABLE 118 LATAM: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 84
5.6 MIDDLE EAST AND AFRICA 85
5.6.1 MEA COUNTRIES HOLD SMALLEST SHARE OF GLOBAL MARKET 85
TABLE 119 MEA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION) 85
TABLE 120 MEA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION) 85
TABLE 121 MEA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION) 86
TABLE 122 MEA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION) 86
TABLE 123 MEA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION) 86
TABLE 124 MEA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION) 86
6 COMPETITIVE LANDSCAPE 87
6.1 OVERVIEW 87
6.2 REVENUE ANALYSIS OF BPH TREATMENT MARKET 87
6.2.1 BPH MARKET REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS 87
FIGURE 8 TOP 5 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS 87
6.3 REVENUE ANALYSIS OF PROSTATE CANCER THERAPEUTICS MARKET 88
6.3.1 PROSTATE CANCER THERAPEUTICS REVENUE ANALYSIS OF TOP 5 MARKET PLAYERS 88
FIGURE 9 TOP 4 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS 88
6.4 MARKET SHARE ANALYSIS, 2020 89
6.4.1 PROSTATE HEALTH MARKET SHARE ANALYSIS, 2020 89
FIGURE 10 PROSTATE HEALTH MARKET SHARE ANALYSIS, 2019 89
6.5 COMPANY EVALUATION MATRIX 90
6.5.1 STARS 90
6.5.2 EMERGING LEADERS 90
6.5.3 PERVASIVE COMPANIES 90
6.5.4 PARTICIPANTS 90
FIGURE 11 PROSTATE HEALTH MARKET: COMPANY EVALUATION MATRIX, 2020 91
7 COMPANY PROFILES 92
7.1 GLAXOSMITHKLINE 92
7.2 ASTELLAS PHARMA 92
7.3 MERCK 93
7.4 ELI LILLY AND COMPANY 93
7.5 ABBOTT LABORATORIES 94
7.6 JOHNSON & JOHNSON SERVICES, INC. 94
7.7 ABBVIE 95
7.8 ASTRAZENECA 95
7.9 SANOFI 96
7.10 PFIZER, INC. 96
8 APPENDIX 97
8.1 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 97
8.2 AVAILABLE CUSTOMIZATIONS 99
8.3 AUTHOR DETAILS 99


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com